On March 22, 2023, EpiBiologics, a biotechnology company building a next-generation antibody-based protein degradation platform for membrane and extracellular drug targets, launched with $50 million in Series A funding. The funding was co-led by Mubadala Capital and Polaris Partners, with participation from Vivo Capital and GV. The company’s technology platform is based on the scientific work of EpiBiologics’ co-founder and renowned antibody engineer Dr. Jim Wells of the University of California, San Francisco (UCSF), and the platform intellectual property has been exclusively licensed from UCSF.

A Wilson Sonsini Goodrich & Rosati team including Julia Minitti, Vern Norviel, Sara Serag, and Rachel Wilson advised EpiBiologics on IP matters related to this transaction.

For more information, please see the EpiBiologics press release.